Suppr超能文献

VI型黏多糖贮积症:一种主要与ARSB基因p.R152W突变纯合性相关的心脏表型。

Mucopolysaccharidosis type VI: a predominantly cardiac phenotype associated with homozygosity for p.R152W mutation in the ARSB gene.

作者信息

Jurecka Agnieszka, Zakharova Ekaterina, Cimbalistiene Loreta, Gusina Nina, Kulpanovich Anna, Golda Adam, Opoka-Winiarska Violetta, Piotrowska Ewa, Voskoboeva Elena, Tylki-Szymańska Anna

机构信息

Department of Molecular Biology, University of Gdańsk, Gdańsk, Poland.

出版信息

Am J Med Genet A. 2013 Jun;161A(6):1291-9. doi: 10.1002/ajmg.a.35905. Epub 2013 Apr 30.

Abstract

Mucopolysaccharidosis type VI (MPS VI) is a rare lysosomal, autosomal recessive storage disorder caused by deficient activity of N-acetylgalactosamine-4-sulfatase (ARSB). Approximately, 140 ARSB gene mutations have been identified; however, most are private mutations making genotype-phenotype correlation for most MPS VI patients difficult. The aim of this study was to describe the natural clinical course in patients homozygous for the p.R152W mutation from eight unrelated families. From our database of 70 patients with MPS VI, we selected 10 patients homozygous for the p.R152W mutant allele (median age 27.5 years, range 18-38 years). We performed a cross-sectional observational study characterizing the onset and prevalence of clinical manifestations. First signs of the disease, such as cardiac valve disease, slightly decreased joint range of motion and mild growth retardation, were observed in mid-adolescent years (median 15 years). Within the disease course, the most common clinical feature in all the patients was progressive heart disease of predominantly valve origin leading to symptoms of heart failure. Other typical MPS VI features were subtle and not present in all the patients. Delays up to 23 years (median 8.5 years) intervened between symptom onset and disease diagnosis. Patients homozygous for the p.R152W mutation present a cardiac variant of MPS VI characterized by progressive cardiac valve disease leading to serious cardiac complications including abrupt death due to cardiac failure.

摘要

VI型黏多糖贮积症(MPS VI)是一种罕见的溶酶体常染色体隐性贮积病,由N - 乙酰半乳糖胺 - 4 - 硫酸酯酶(ARSB)活性缺乏引起。大约已鉴定出140种ARSB基因突变;然而,大多数是个别突变,这使得大多数MPS VI患者的基因型 - 表型相关性难以确定。本研究的目的是描述来自8个无关家族的p.R152W突变纯合子患者的自然临床病程。从我们70例MPS VI患者的数据库中,我们选择了10例p.R152W突变等位基因纯合子患者(中位年龄27.5岁,范围18 - 38岁)。我们进行了一项横断面观察性研究,以确定临床表现的起病情况和患病率。在青春期中期(中位年龄15岁)观察到疾病的首发症状,如心脏瓣膜病、关节活动范围略有减小和轻度生长发育迟缓。在疾病过程中,所有患者最常见的临床特征是主要起源于瓣膜的进行性心脏病,导致心力衰竭症状。其他典型的MPS VI特征不明显,并非所有患者都有。症状出现与疾病诊断之间的间隔长达23年(中位8.5年)。p.R152W突变纯合子患者表现出MPS VI的心脏变异型,其特征为进行性心脏瓣膜病,导致严重的心脏并发症,包括因心力衰竭突然死亡。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验